Advertisement
Screener

Nektar Therapeutics (NKTR) Restructuring Charges

2.8 / 5 stars · 68/120 Roast Me

Nektar Therapeutics Restructuring Charges

Nektar Therapeutics (NKTR) reported Restructuring Charges of $16.83 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-04.

Discontinued › Expense Statement › Operating Expenses

us-gaap:RestructuringCharges · last filed 2022-11-04

  • Nektar Therapeutics restructuring charges for the quarter ending 2022-09-30 was $16.83M.
  • Nektar Therapeutics restructuring charges for the quarter ending 2022-06-30 was $106.05M.
  • Nektar Therapeutics restructuring charges for the quarter ending 2022-03-31 was $1.48M.
  • Nektar Therapeutics restructuring charges for the quarter ending 2021-09-30 was $0.00.
Period endRestructuring Charges 3 monthRestructuring Charges 6 monthRestructuring Charges 9 month
2022-09-30$16.83M
10-Q · filed 2022-11-04
$122.88M
derived: sum of 2 quarters · filed 2022-11-04
$124.35M
10-Q · filed 2022-11-04
2022-06-30$106.05M
10-Q · filed 2022-08-05
$107.52M
10-Q · filed 2022-08-05
2022-03-31$1.48M
10-Q · filed 2022-05-06
2021-09-30$0.00
10-Q · filed 2022-11-04
$0.00
derived: sum of 2 quarters · filed 2022-11-04
$0.00
10-Q · filed 2022-11-04
2021-06-30$0.00
10-Q · filed 2022-08-05
$0.00
10-Q · filed 2022-08-05
2021-03-31$0.00
10-Q · filed 2022-05-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
UroGen Pharma Ltd. (URGN)$2.015B-18.42
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
Generate Biomedicines, Inc. (GENB)United States$2.052B
Biohaven Ltd. (BHVN)United States$1.990B-3.83
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89